U.S. Markets open in 5 hrs 39 mins

Verona Pharma plc : Block Listing Update

LONDON, May 31, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (VRP.L) (VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, provides the following update on its block listing, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listing arrangements, put in place from 29 July 2016: 

Name of applicant: Verona Pharma plc
Name of scheme: 2016 Warrant Shares
Period of return: From 1 December 2017 to 31 May 2018
Balance of unallotted securities under scheme(s) from previous return: 12,446,370 Ordinary Shares of 5 pence each
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for): Nil
Less: Number of securities issued/allotted under scheme(s) during period Nil
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 12,446,370 Ordinary Shares of 5 pence each
Number and class of share(s) (amount of stock/debit securities) originally admitted and the Date of Admission: 10,262,879 on 29 July 2016

 

Name of contact: Claire Poll
Telephone number of contact: +44 (0)20 3283 4200

ENDS

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
   
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison  

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma`s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verona Pharma plc via GlobeNewswire

HUG#2196216